Perfluorohexyloctane Eye Drops (PFHO)

Approved

BBeijing Tongren Hospital

Perfluorohexyloctane Eye Drops (PFHO) is one of 3 therapeutic programs targeting Dry Eye. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Dry EyeNot yet recruiting

Dry EyeApproved

Not yet recruiting

Competition

Competitive Landscape

4 competitors in Dry Eye

#DrugCompanyPhaseTrials

Miebo

BBausch & Lomb Incorporated

Approved

1 2

Perfluorohexyloctane Eye Drops (PFHO)

BBeijing Tongren Hospital

Approved

1 3

Accutane

CConrado Roberto Hoffmann Filho

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

ApprovedNot yet recruiting

Dry Eye

NCT07679685

Clinical

Trials by Indication[1]

Dry Eye1 trial

A Prospective, Multicenter, Randomized Controlled Trial on the Efficacy and Safety of Perfluorohexyloctane Eye Drops Versus 0.1% Sodium Hyaluronate Eye Drops in the Treatment of Video Display Terminal-associated Dry Eye

Not yet recruiting·BBeijing Tongren Hospital·Approved·NCT07679685·159 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Perfluorohexyloctane Eye Drops (PFHO). U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Perfluorohexyloctane Eye Drops (PFHO). EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Beijing Tongren Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Approved[1]
Company: BBeijing Tongren Hospital

Perfluorohexyloctane Eye Drops (PFHO)

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Dry Eye1 trial

References

Drug Info

Quick Facts

Related News